(BCAT) BlackRock Capital - Ratings and Ratios
Equities, Bonds, Preferred, Convertibles, Options
Dividends
| Dividend Yield | 23.15% |
| Yield on Cost 5y | 28.24% |
| Yield CAGR 5y | 28.55% |
| Payout Consistency | 99.0% |
| Payout Ratio | 226.7% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 12.0% |
| Value at Risk 5%th | 19.9% |
| Relative Tail Risk | 0.58% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.55 |
| Alpha | 1.86 |
| CAGR/Max DD | 1.28 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.338 |
| Beta | 0.551 |
| Beta Downside | 0.534 |
| Drawdowns 3y | |
|---|---|
| Max DD | 13.69% |
| Mean DD | 1.99% |
| Median DD | 1.29% |
Description: BCAT BlackRock Capital November 13, 2025
BlackRock Capital Allocation Trust (NYSE: BCAT) is a U.S.-based closed-end fund that trades as common stock and is classified under the GICS sub-industry “Asset Management & Custody Banks.” The trust’s mandate is to allocate capital across a diversified set of equities, fixed income, and alternative assets, aiming to generate total return through active management.
As of the latest filing (Q2 2024), BCAT reported assets under management of roughly $1.2 billion and an expense ratio of 0.84%, which is modest relative to peer closed-end funds. The fund’s 30-day SEC-yield stands at about 5.3%, reflecting its exposure to higher-yielding fixed-income securities in a rising-rate environment. Recent performance shows a year-to-date total return of ~ 6.8%, outpacing the S&P 500’s ~ 5.5% return over the same period.
Key drivers for BCAT’s outlook include the Federal Reserve’s monetary policy trajectory (higher rates generally boost income-producing assets but can pressure equity valuations), the ongoing consolidation in the asset-management industry that may enhance fee-related earnings, and the fund’s flexibility to shift allocations toward sectors benefiting from fiscal spending, such as infrastructure and technology.
For a deeper quantitative breakdown, you might explore the ValueRay platform’s metric suite to see how BCAT’s risk-adjusted returns compare across similar closed-end funds.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (194.4m TTM) > 0 and > 6% of Revenue (6% = 11.9m TTM) |
| FCFTA 0.19 (>2.0%) and ΔFCFTA 10.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -96.73% (prev -73.99%; Δ -22.75pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 354.9m > Net Income 194.4m (YES >=105%, WARN >=100%) |
| Net Debt (-6.30m) to EBITDA (194.4m) ratio: -0.03 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.03 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (104.8m) change vs 12m ago -3.11% (target <= -2.0% for YES) |
| Gross Margin 98.35% (prev 0.0%; Δ 98.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 10.01% (prev 9.93%; Δ 0.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 138.5 (EBITDA TTM 194.4m / Interest Expense TTM 1.40m) >= 6 (WARN >= 3) |
Altman Z'' -0.52
| (A) -0.10 = (Total Current Assets 6.30m - Total Current Liabilities 197.5m) / Total Assets 1.87b |
| (B) -0.04 = Retained Earnings (Balance) -79.8m / Total Assets 1.87b |
| (C) 0.10 = EBIT TTM 194.4m / Avg Total Assets 1.97b |
| (D) -0.36 = Book Value of Equity -79.8m / Total Liabilities 224.0m |
| Total Rating: -0.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.73
| 1. Piotroski 8.0pt |
| 2. FCF Yield 24.36% |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -0.03 |
| 6. ROIC - WACC (= 1.33)% |
| 7. RoE 10.94% |
| 8. Revenue Trend data missing |
| 9. EPS Trend -46.77% |
What is the price of BCAT shares?
Over the past week, the price has changed by +2.77%, over one month by +0.12%, over three months by +2.20% and over the past year by +11.12%.
Is BCAT a buy, sell or hold?
What are the forecasts/targets for the BCAT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 20 | 38.3% |
BCAT Fundamental Data Overview November 24, 2025
P/E Trailing = 9.2318
P/S = 9.1644
P/B = 0.8896
Beta = None
Revenue TTM = 197.7m USD
EBIT TTM = 194.4m USD
EBITDA TTM = 194.4m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -6.30m USD (from netDebt column, last fiscal year)
Enterprise Value = 1.46b USD (1.46b + (null Debt) - CCE 3.88m)
Interest Coverage Ratio = 138.5 (Ebit TTM 194.4m / Interest Expense TTM 1.40m)
FCF Yield = 24.36% (FCF TTM 354.9m / Enterprise Value 1.46b)
FCF Margin = 179.5% (FCF TTM 354.9m / Revenue TTM 197.7m)
Net Margin = 98.35% (Net Income TTM 194.4m / Revenue TTM 197.7m)
Gross Margin = 98.35% ((Revenue TTM 197.7m - Cost of Revenue TTM 3.25m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.78 (Enterprise Value 1.46b / Total Assets 1.87b)
Interest Expense / Debt = unknown (Interest Expense 1.40m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 153.6m (EBIT 194.4m * (1 - 21.00%))
Current Ratio = 0.03 (Total Current Assets 6.30m / Total Current Liabilities 197.5m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -0.03 (Net Debt -6.30m / EBITDA 194.4m)
Debt / FCF = -0.02 (Net Debt -6.30m / FCF TTM 354.9m)
Total Stockholder Equity = 1.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.42% (Net Income 194.4m / Total Assets 1.87b)
RoE = 10.94% (Net Income TTM 194.4m / Total Stockholder Equity 1.78b)
RoCE = 11.65% (EBIT 194.4m / Capital Employed (Total Assets 1.87b - Current Liab 197.5m))
RoIC = 9.38% (NOPAT 153.6m / Invested Capital 1.64b)
WACC = 8.05% (E(1.46b)/V(1.46b) * Re(8.05%) + (debt-free company))
Discount Rate = 8.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -1.26%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈285.5m ; Y1≈352.2m ; Y5≈600.8m
Fair Price DCF = 97.53 (DCF Value 10.22b / Shares Outstanding 104.8m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -46.77 | EPS CAGR: -94.86% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
Additional Sources for BCAT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle